Thelansis

Chikungunya is a zoonotic illness caused by the Chikungunya virus (CHIKV) and is spread through the bites of infected Aedes aegypti, Aedes albopictus, and Aedes polynesienses mosquitoes. This disease typically manifests with a sudden onset of fever and severe joint pain. Additionally, individuals may experience symptoms like headaches, muscle pain, fatigue, and a rash. The incubation period varies from 1 to 12 days, with an average of 2 to 7 days. CHIKV infection results in high viremia levels, usually persisting for 4 to 6 days after symptoms emerge. Most people infected with CHIKV exhibit symptoms, while less than 15% experience asymptomatic seroconversion. Various laboratory tests are available to diagnose CHIK, utilizing serum or plasma samples to detect the virus, viral nucleic acid, virus-specific immunoglobulin (Ig) IgM, and neutralizing antibodies. Currently, there is no vaccine or specific medication for treating Chikungunya. However, palliative treatments are available, inclu...

  Chikungunya is a viral illness transmitted by mosquitoes that causes the sudden onset of fever and extreme joint pain. Other signs and symptoms may include headache, muscle pain, fatigue and rash. Symptoms usually appear within a week of infection, fever and joint pain come on suddenly. Muscle pain, headache, fatigue and rash may also occur. Thelansis’s “Chikungunya Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chikungunya treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Chikungunya across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around curren...